Profile data is unavailable for this security.
About the company
Chemomab Therapeutics Ltd, formerly known as Anchiano Therapeutics Ltd, is a Israel-based biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of cancers. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.
- Revenue in USD (TTM)0.00
- Net income in USD-15.00m
- Incorporated2011
- Employees20.00
- LocationChemomab Therapeutics LtdKiryat Atidim, Building 7TEL AVIV-YAFO 6158002IsraelISR
- Phone+972 773310156
- Websitehttps://www.chemomab.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RenovoRx Inc | 0.00 | -8.11m | 29.26m | 8.00 | -- | 3.15 | -- | -- | -0.6059 | -0.6059 | 0.00 | 0.3868 | 0.00 | -- | -- | 0.00 | -88.58 | -- | -106.00 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -3.47 | -- | -- | -- |
| Longeveron Inc | 1.23m | -27.90m | 29.29m | 23.00 | -- | 1.31 | -- | 23.84 | -8.75 | -8.75 | 0.3641 | 1.55 | 0.0674 | -- | 7.83 | 53,434.78 | -101.98 | -63.15 | -127.46 | -75.68 | 58.99 | 33.70 | -1,513.83 | -441.02 | -- | -- | 0.00 | -- | -41.98 | -19.78 | -17.92 | -- | 26.80 | -- |
| Vyne Therapeutics Inc | 486.00k | -27.86m | 29.35m | 10.00 | -- | 0.3864 | -- | 60.39 | -2.41 | -2.57 | 0.0162 | 5.15 | 0.0087 | -- | -- | 48,600.00 | -49.92 | -108.41 | -59.60 | -138.57 | -- | -- | -5,732.31 | -1,907.10 | -- | -- | 0.00 | -- | -11.11 | -47.51 | 17.89 | -- | -- | -- |
| Mink Therapeutics Inc | 0.00 | -17.09m | 29.81m | 31.00 | -- | -- | -- | -- | -0.4891 | -0.4891 | 0.00 | -0.4202 | 0.00 | -- | -- | 0.00 | -152.35 | -- | -4,151.28 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 19.77 | -- | -- | -- |
| Raphael Pharmaceutical Inc | 0.00 | -1.40m | 30.86m | 0.00 | -- | -- | -- | -- | -0.0803 | -0.0803 | 0.00 | -0.0155 | 0.00 | -- | -- | -- | -1,134.41 | -- | -- | -- | -- | -- | -- | -- | -- | -139.10 | -- | -- | -- | -- | 61.76 | -- | -- | -- |
| SAB Biotherapeutics Inc | 2.78m | -40.32m | 31.29m | 57.00 | -- | 0.6784 | -- | 11.25 | -5.69 | -5.69 | 0.3646 | 5.00 | 0.0571 | -- | 9.44 | 48,773.51 | -82.85 | -- | -102.37 | -- | -- | -- | -1,450.32 | -- | -- | -- | 0.0817 | -- | -90.63 | -- | -125.14 | -- | -- | -- |
| AN2 Therapeutics Inc | 0.00 | -64.66m | 31.33m | 41.00 | -- | 0.3185 | -- | -- | -2.26 | -2.26 | 0.00 | 3.30 | 0.00 | -- | -- | 0.00 | -62.35 | -- | -69.48 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -51.33 | -- | -- | -- |
| Chemomab Therapeutics Ltd - ADR | 0.00 | -15.00m | 31.65m | 20.00 | -- | 2.46 | -- | -- | -7.69 | -7.69 | 0.00 | 0.6954 | 0.00 | -- | -- | 0.00 | -69.12 | -- | -92.98 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 12.39 | -- | -- | -- |
| Lumos Pharma Inc | 1.49m | -35.75m | 31.93m | 33.00 | -- | 3.11 | -- | 21.49 | -4.43 | -4.43 | 0.1841 | 1.26 | 0.0382 | -- | 7.41 | 45,030.30 | -91.98 | -29.78 | -107.92 | -32.32 | -- | -- | -2,405.72 | -2,937.61 | -- | -- | 0.00 | -- | 34.67 | -30.31 | -9.57 | -- | -- | -- |
| Ocean Biomedical Inc | 0.00 | -98.59m | 32.22m | 9.00 | -- | -- | -- | -- | -3.01 | -3.01 | 0.00 | -2.21 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -0.2443 | -- | -- | -- | -- | 72.16 | -- | -- | -- |
| Clene Inc. | 442.00k | -30.46m | 32.35m | 82.00 | -- | -- | -- | 73.19 | -4.74 | -4.74 | 0.0688 | -0.0783 | 0.0082 | 1.89 | 5.49 | 5,390.24 | -56.31 | -39.43 | -81.90 | -47.32 | 81.00 | -- | -6,890.50 | -5,261.20 | 0.993 | -16.96 | 1.02 | -- | 38.27 | -- | -65.47 | -- | -- | -- |
| Acurx Pharmaceuticals Inc | 0.00 | -16.73m | 32.65m | 4.00 | -- | 9.38 | -- | -- | -1.15 | -1.15 | 0.00 | 0.2143 | 0.00 | -- | -- | 0.00 | -211.55 | -- | -346.94 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.55 | -- | -- | -- |
| Tempest Therapeutics Inc | 0.00 | -31.75m | 34.03m | 17.00 | -- | 1.95 | -- | -- | -1.64 | -1.64 | 0.00 | 0.6921 | 0.00 | -- | -- | 0.00 | -87.09 | -57.10 | -127.72 | -71.20 | -- | -- | -- | -- | -- | -368.16 | 0.3861 | -- | -- | -- | 17.41 | -- | 36.40 | -- |
Data as of Sep 23 2024. Currency figures normalised to Chemomab Therapeutics Ltd's reporting currency: US Dollar USD
2.96%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Ikarian Capital LLCas of 31 Mar 2024 | 213.39k | 1.50% |
| Two Sigma Investments LPas of 31 Mar 2024 | 39.99k | 0.28% |
| Two Sigma Advisers LPas of 31 Mar 2024 | 37.80k | 0.27% |
| Kestra Private Wealth Services LLCas of 31 Mar 2024 | 31.24k | 0.22% |
| Boothbay Fund Management LLCas of 31 Mar 2024 | 26.53k | 0.19% |
| Two Sigma Securities LLCas of 31 Mar 2024 | 26.19k | 0.18% |
| RhumbLine Advisers LPas of 30 Jun 2024 | 19.88k | 0.14% |
| Geode Capital Management LLCas of 30 Jun 2024 | 11.74k | 0.08% |
| G1 Execution Services LLCas of 31 Mar 2024 | 11.48k | 0.08% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Mar 2024 | 2.80k | 0.02% |
More ▼
Data from 31 Mar 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
